.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Novartis
Argus Health
Citi
McKesson
Chinese Patent Office
Johnson and Johnson
Healthtrust
Federal Trade Commission
AstraZeneca

Generated: September 20, 2017

DrugPatentWatch Database Preview

ONSOLIS Drug Profile

« Back to Dashboard

Which patents cover Onsolis, and when can generic versions of Onsolis launch?

Onsolis is a drug marketed by Bdsi and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in ONSOLIS is fentanyl citrate. There are thirty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.

Summary for Tradename: ONSOLIS

Patents:3
Applicants:1
NDAs:1
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ONSOLIS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-001Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-003Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-002Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-004Jul 16, 2009DISCNNoNo► Subscribe► Subscribe ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-003Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-005Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-001Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-001Jul 16, 2009DISCNNoNo► Subscribe► Subscribe ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-002Jul 16, 2009DISCNNoNo► Subscribe► Subscribe ► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-002Jul 16, 2009DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ONSOLIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-001Jul 16, 2009► Subscribe► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-002Jul 16, 2009► Subscribe► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-005Jul 16, 2009► Subscribe► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-004Jul 16, 2009► Subscribe► Subscribe
Bdsi
ONSOLIS
fentanyl citrate
FILM;BUCCAL022266-003Jul 16, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ONSOLIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,800,832 Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces► Subscribe
9,655,843Transmucosal delivery devices with enhanced uptake► Subscribe
8,147,866Transmucosal delivery devices with enhanced uptake► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ONSOLIS

Country Document Number Estimated Expiration
European Patent Office2054031► Subscribe
Japan5689144► Subscribe
Israel196529► Subscribe
Canada2658585► Subscribe
Canada2268187► Subscribe
China103550136► Subscribe
Portugal973497► Subscribe
BrazilPI0714712► Subscribe
New Zealand574361► Subscribe
Canada2329128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ONSOLIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0653Netherlands► SubscribePRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
00653Netherlands► SubscribePRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
2014 00016Denmark► SubscribePRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
2011000009Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
2014000024Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Accenture
Harvard Business School
Queensland Health
Deloitte
AstraZeneca
Argus Health
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot